St. John's Wort for depressive disorders: results of an outpatient study with the Hypericum preparation HYP 811.
The efficacy and tolerability of a high-dose formulation of St. John's Wort extract, HYP 811, was tested in 607 patients in a 6-week, prospective, multicenter, postmarketing surveillance study. Severity of depression was assessed by physicians using the Hamilton Depression Scale; patient self-evaluation was performed using the von Zerssen Depression Scale. After 6 weeks of treatment, both scores improved by approximately 60%, on average. Disturbances in well-being, such as dejection, loss of interest, and generalized physical complaints, diminished during therapy. The tolerability of HYP 811 was rated "very good" and "good" in 89.4% of cases. After 3 weeks of treatment, dosage in 128 patients (21.1%) was successfully reduced to one capsule daily.
Mueller
B M
BM
Biocur Arzneimittel GmbH, Holzkirchen, Germany.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000553:Ambulatory Care; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010569:Perylene / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010936:Plant Extracts / Q000627:therapeutic use*; D011358:Product Surveillance, Postmarketing; D011446:Prospective Studies; D011794:Quercetin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome; D014966:Xanthenes / Q000627:therapeutic use*
D000928:Antidepressive Agents; D010569:Perylene; D010936:Plant Extracts; D011794:Quercetin; D017367:Selective Serotonin Reuptake Inhibitors; D014966:Xanthenes